WHO says partners can start talks to buy mpox vaccines before its approval
Adds Gavi comment, paragraphs 9-10
WHO partners such as Gavi and UNICEF can buy mpox vaccines before approval
Bavarian Nordic and KM Biologics vaccines already approved in US and Japan
Gavi prioritizes donated doses, ready to procure once demand is clear
By Jennifer Rigby
LONDON, Aug 23 (Reuters) -The World Health Organization said on Friday its partners such as Gavi and UNICEF can start buying mpox vaccines before they are approved by the U.N. health agency, to get inoculations to Africa faster as the continent battles an escalating outbreak of the virus.
Traditionally, organisations like Gavi, which helps lower-income countries buy vaccines, can only start purchasing shots once they have approval from the WHO. But the rules have been relaxed in this instance to get talks moving, as the WHO's approval is due in a few weeks.
Two vaccines, made by Denmark's Bavarian Nordic BAVA.CO and Japan's KM Biologics, are already approved by regulators around the world, including the U.S. and Japan, and have been in widespread use for mpox since 2022. Around 1.2 million people have had Bavarian Nordic's vaccine in the U.S. alone. The WHO is expected to grant an emergency licence to the shots in September.
Mpox, a viral infection that spreads through close contact and is usually mild but can kill, was declared a public emergency of international concern by the WHO last week after a new offshoot of the virus spread quickly in Democratic Republic of Congo and beyond.
Earlier this month, the WHO asked vaccine manufacturers to submit information so it could accelerate its approval process, and grant an emergency licence by mid-September.
However this week, one of the vaccine manufacturers, Bavarian Nordic, said it needed orders immediately from organisations such as Gavi and the WHO to make more shots this year, raising fears that lower-income countries could miss out or be forced to rely on precarious donations from high-income countries, as happened during the COVID-19 pandemic.
Some donated mpox vaccines are due to arrive in Africa next week, the Africa Centres for Disease Control and Prevention has said. The agency has said 10 million doses are needed.
"While we see the news from WHO as a positive, we are not able to comment on specific negotiations. We will update the market in due time if and when orders materialize," a spokesperson for Bavarian Nordic said.
A spokesperson for Gavi said that getting donated doses to countries, and into vaccination programmes, was the first priority.
"When it comes to procuring vaccines directly, since a public health emergency of international concern was announced last week, we have intensified our efforts, with near-daily contact with manufacturers: we are ready to go as soon as we get a clear picture on demand,” the spokesperson said.
KM Biologics did not immediately respond to requests for comment.
Reporting by Jennifer Rigby, additional reporting by Maggie Fick
Editing by Christina Fincher, Susan Fenton, William Maclean and Rod Nickel
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
